Free Trial
NASDAQ:INSM

Insmed Q3 2025 Earnings Report

Insmed logo
$157.16 +4.36 (+2.85%)
Closing price 04:00 PM Eastern
Extended Trading
$156.60 -0.56 (-0.36%)
As of 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insmed EPS Results

Actual EPS
N/A
Consensus EPS
-$1.35
Beat/Miss
N/A
One Year Ago EPS
N/A

Insmed Revenue Results

Actual Revenue
N/A
Expected Revenue
$114.33 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Insmed Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, October 30, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Insmed Earnings Headlines

TD Cowen Maintains Insmed (INSM) Buy Recommendation
Analyst Expectations For Insmed's Future
Alert: Prepare for Trump's Dollar Overhaul
President Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best."tc pixel
Ohio Retirement Fund Invests in Insmed Incorporated (INSM)
See More Insmed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Insmed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Insmed and other key companies, straight to your email.

About Insmed

Insmed (NASDAQ:INSM) Incorporated is a biopharmaceutical company headquartered in Bridgewater, New Jersey, specializing in the development and commercialization of therapies for rare and serious diseases. The company’s lead product, Arikayce (amikacin liposome inhalation suspension), is approved for the treatment of Mycobacterium avium complex (MAC) lung disease in adults who have limited or no alternative treatment options. Insmed’s work in developing inhaled and targeted therapies underscores its commitment to addressing high unmet medical needs in pulmonary and systemic rare diseases.

In addition to its marketed product, Insmed has built a pipeline of clinical-stage candidates aimed at improving outcomes for patients with serious respiratory conditions. Among these is brensocatib, an investigational treatment for non-cystic fibrosis bronchiectasis, which is being evaluated for its ability to inhibit neutrophil serine proteases and reduce lung inflammation. The company is also advancing preclinical programs that leverage its expertise in drug delivery and formulation to pursue novel approaches in other therapeutic areas.

Founded in the late 1980s and formerly known as Transave, Insmed adopted its current name in the early 2000s as it refocused its business on rare diseases. The company completed its initial public offering in 2013, raising capital to support late-stage development of key programs. Over time, Insmed has formed strategic collaborations and in-licensed assets to broaden its pipeline and position itself as a leader in rare disease research.

Insmed’s operations extend beyond the United States, with regulatory interactions and development activities in Europe, Japan and other regions where rare pulmonary and systemic diseases pose significant healthcare challenges. Under the leadership of Chief Executive Officer Will Lewis, the company continues to invest in clinical research, manufacturing capabilities and global commercial infrastructure to bring new treatment options to patients in need.

View Insmed Profile

More Earnings Resources from MarketBeat